Navigation Links
Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
Date:8/8/2008

WALTHAM, Mass., Aug. 8 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of near-patient diagnostics, monitoring and health management solutions, is featuring its new TB diagnostic test, the Clearview TB ELISA, at the International AIDS conference (AIDS 2008).

The test, which was introduced to developing world markets in July 2008, provides a much needed aid in the diagnosis of Mycobacterium tuberculosis (TB) in TB/HIV co-infected patients. By providing reliable information more quickly, when compared to other methods, the Clearview TB ELISA can enable treatment decisions to be made the very same day, allowing for more effective patient health management and mitigating the risk of further transmission to a highly vulnerable population.

The Clearview TB ELISA has shown strong performance in detecting TB in those co-infected with HIV. Clearview TB ELISA uses antibodies specific to the antigen lipoarabinomannan (LAM). Elevated levels of the LAM antigen within the urine of TB/HIV co-infected patients provides a specific and reliable diagnostic target. Clinical data shows that, while microscopy methods detect TB in these TB/HIV co-infected patients, at rates as low as 20%, targeting the LAM antigen using the Clearview TB ELISA can produce detection rates of 80%.

Ron Zwanziger, Inverness' CEO stated, "Introduction of the Clearview TB ELISA is an important first step in making available much-needed diagnostic tools to address the TB epidemic where the need is greatest. We are working hard to build support for its widespread adoption."

There were approximately 33 million people living with HIV infection in 2007 and due to their compromised immune status, more than one third we
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
2. Inverness Medical Innovations Announces Second Quarter 2008 Results
3. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
4. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
5. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
6. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
7. Inverness Medical Innovations to Participate at Morgan Stanley Global Healthcare Unplugged Conference on April 30, 2008
8. Inverness Medical Innovations Announces First Quarter 2008 Results
9. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
10. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
11. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
(Date:8/28/2014)... Grove, PA (PRWEB) August 28, 2014 ... and create a culture that will allow individuals to ... are becoming increasingly important for employers looking to compete ... science industries are embracing this trend, as the sector ... fabric of a company, which will have real results ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... sponges, IUDs, diaphragms-- women have many options for planning their ... men want to help out? They have only two options ... crucial for dating but get old in long-term relationships. ... that nobody is every calling them "Daddy" before they are ...
... PPD, Inc. (Nasdaq:,PPDI) will release its third quarter 2007 ... The earnings release will be available,on the PPD Web ... On Wednesday, October 24, at 9 a.m. ET, ... to discuss financial results and the,overall business environment. A ...
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
Cached Biology Technology:Of mice and men: new male contraceptives successful in rodents and humans 2PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4
(Date:8/28/2014)... for delivering compounds that could positively impact ... may be possible, thanks to researchers in ... semi-soft vaginal suppository made from the seaweed-derived ... antiviral drug Tenofovir provides a woman-initiated, drug-delivery ... of sexually transmitted infections during unprotected heterosexual ...
(Date:8/28/2014)... August 28, 2014 Dyslexia, the most commonly ... a neurological reading disability that occurs when the ... don,t function normally. , The use of non-invasive ... activity is disrupted in dyslexia. However, most prior ... of brain regions, leaving a gap in our ...
(Date:8/28/2014)... the first person to alert the world to Global ... be captured and stored underground. He says that Carbon ... the best way to avoid global warming getting out ... (Columbia University, New York) made the call during his ... where 150 scientists are meeting to discuss Carbon Capture ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Dyslexic readers have disrupted network connections in the brain 2Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2
... and molecular biologists, chemists, physicists, material scientists, computational modelers ... the newly funded Center for Lignocellulose Structure and Formation, ... Penn State. The DOE plans to fund the ... Cosgrove, professor of biology, will direct the Center in ...
... human brain stores some kinds of memories for a ... at things, our gray matter also creates temporary memories ... seconds these visual memories exist. For decades, scientists have ... grow gradually more imprecise over the course of several ...
... A new longitudinal study of children,s personality traits ... differently in girls and boys. The study, by ... of Hawaii at Manoa, and Purdue University, appears ... Child Development . The researchers looked ...
Cached Biology News:Center to investigate plant cells for better biomass fuels 2Some short-term memories die suddenly, no fading 2Sugar, spice and puppy dog tails: Developing sex-typed personality traits and interests 2
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
... SLi 3 •3H 2 O Formula Weight: 881.42 ... pH 7.0): greater than or equal to 90% lambda max : 259 ... Spectral Ratios: A 232 /A 260 : 0.51 ... 280 /A 260 : 0.17 0.02 Storage: -20C ...
Biology Products: